Open AccessOnline Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
Author(s) -
Pedro Such,
J.M. Olivares,
Lizbeth Arias,
Mette Troels Berg,
Jessica J Madera
Publication year - 2021
Publication title -
neuropsychiatric disease and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.819
H-Index - 67
eISSN - 1178-2021
pISSN - 1176-6328
DOI - 10.2147/ndt.s303292
Subject(s) - medicine , aripiprazole , paliperidone palmitate , schizophrenia (object oriented programming) , global assessment of functioning , pharmacology , antipsychotic , psychiatry
To obtain real-world evidence of functional improvements during atypical long-acting injectable (aLAI) therapy in recent-onset schizophrenia, an online survey was conducted to assess the impact of aripiprazole once-monthly injectable 400 mg (AOM 400; partial D 2 receptor agonist) and paliperidone palmitate once-monthly (PP1M; injectable, full D 2 receptor antagonist).